NCT03468322View on ClinicalTrials.gov

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 20, 2018

Primary Completion Date

April 9, 2019

Study Completion Date

April 9, 2019

Conditions
Inherited Epidermolysis Bullosa
Interventions
DRUG

AC-203

The investigational product is formulated as 1% topical ointment

DRUG

Vehicle

Vehicle-only control study medication is the same formulation as investigational product without active ingredient

Trial Locations (2)

Unknown

Mackay Memorial Hospital, Hsinchu

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

TWi Biotechnology, Inc.

INDUSTRY

NCT03468322 - A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients | Biotech Hunter | Biotech Hunter